A new CAR T-cell therapy attacks supportive cells in the tumor microenvironment that bear the surface protein, uPAR.

Officials at Caring Cross emphasize that the organization is dedicated to ensuring the global affordability of advanced therapies.

Missing gut bacteria may prevent some people with celiac disease from fully benefiting from high-fiber supplements or diets [DrAfter123 / DigitalVision Vectors/] The autoimmune disorder celiac disease ...

Large‑scale protein evolution model reveals that common ancestry, not selection or epistasis, is the dominant force limiting ...

Over the past decade, scientists have identified numerous genetic variants that confer substantial risk for autism and other neurodevelopmental disorders. However, most of these discoveries were made ...

Study identifies impaired ER-to-golgi ceramide transport as a key regulatory node underlying senescence-associated sphingolipid remodeling.

AI is not overhyped. The potential requires equal attention to the less glamorous but more important role of data management.

The big pharma and AI drug developer expand on a partnership that launched with a 2023 software licensing accord.

Disappointed investors punished Wave Life Sciences (NASDAQ: WVE), causing its shares to lose roughly half their value on Thursday after the RNA-based drug developer reported mixed early-stage interim ...

The data showed that roughly 65% of the cells in the oxygenated devices remained viable compared to roughly 20% in control devices.

Researchers suggest modulating intestinal microbiota or antigen-presenting activity of IECs represents new approaches to treating autoimmune neurological disease.

Many organizations still lack structured media optimization and alignment between development and manufacturing, according to Lonza.